文献速递临床试验与 GCP

富血小板血浆注射与假注射对慢性中段跟腱病肌腱功能障碍的影响:随机临床试验

Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项多中心随机临床试验纳入240例慢性中段跟腱病患者,比较单次肌腱内富血小板血浆注射与假注射(皮下干针不进入肌腱)对VISA-A评分的影响。6个月随访时,两组VISA-A评分分别为54.4与53.4,校正均数差-2.7(95%CI -8.8至3.3),未显示富血小板血浆注射改善跟腱功能障碍。

要点

  • 单次肌腱内富血小板血浆注射未改善慢性中段跟腱病6个月时的VISA-A评分。
  • 注射部位不适在富血小板血浆组97例、假注射组73例,为最常见不良事件。
  • 结果不支持使用单次富血小板血浆注射治疗慢性中段跟腱病。

核心结论

  • 在慢性中段跟腱病患者中,与皮下干针假注射相比,单次肌腱内富血小板血浆注射未减轻6个月时的跟腱功能障碍。
  • 这些发现不支持将该治疗用于慢性中段跟腱病。

研究设计与样本

  • 参与者盲法、多中心随机临床试验,纳入24个中心的240例患者,2016年4月至2020年2月分配至富血小板血浆注射或假注射,最终随访至2020年7月。
  • 纳入标准为年龄大于18岁、经超声或磁共振成像或两者确认的中段跟腱疼痛持续超过3个月。
  • 干预为单次肌腱内富血小板血浆注射(n=121)或单次假注射(皮下干针插入不进入肌腱,n=119)。
  • 主要结局为治疗分配后6个月测量的VISA-A评分,范围0(最差症状)至100(无症状),最小临床重要差异为12分;主要分析校正侧别、年龄、性别和基线VISA-A评分。

主要发现

  • 240例患者平均年龄52岁,女性138例(58%),221例(92%)完成试验。
  • 6个月随访时,富血小板血浆组与假注射组的平均VISA-A评分分别为54.4与53.4,校正均数差-2.7(95%CI -8.8至3.3)。
  • 富血小板血浆组与假注射组最常见不良事件分别为注射部位不适(97例 vs 73例)、肿胀(56例 vs 52例)和瘀斑(48例 vs 49例)。

关键数值与推荐

  • 主要结局VISA-A评分包含8个问题,覆盖疼痛、功能和活动3个领域,以复合评分分析,范围0至100,最小临床重要差异为12分。

临床怎么用

  • 对于慢性中段跟腱病患者,单次肌腱内富血小板血浆注射不应作为改善跟腱功能障碍的常规治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Platelet-rich plasma injections are used as a treatment for chronic midportion Achilles tendinopathy, but evidence for this treatment is limited. OBJECTIVE: In adults with midportion Achilles tendinopathy, to assess the effects of a single platelet-rich plasma injection, compared with sham injection, on the outcome of the Victorian Institute of Sport Assessment-Achilles (VISA-A) score (a single composite measure of Achilles tendinopathy severity). DESIGN, SETTING, AND PARTICIPANTS: A participant-blinded, multicenter randomized clinical trial that included 240 people from 24 sites assigned to either a platelet-rich plasma injection or a sham injection between April 2016 and February 2020. Final follow-up was July 2020. Participants were older than 18 years with midportion Achilles tendon pain for more than 3 months as confirmed by ultrasound, magnetic resonance imaging, or both. INTERVENTIONS: A single intratendinous platelet-rich plasma injection (n = 121) or a single sham injection (insertion of a subcutaneous dry needle not entering the tendon) (n = 119). MAIN OUTCOMES AND MEASURES: The primary outcome was the VISA-A score, measured 6 months after treatment allocation. The VISA-A score contains 8 questions that cover 3 domains of pain, function, and activity, analyzed as a composite score (range, 0 [worst symptoms] to 100 [no symptoms]; minimal clinically important difference in score, 12 points). The primary analysis was adjusted for laterality, age, sex, and baseline VISA-A score. RESULTS: Among 240 patients assigned to a platelet-rich plasma or sham injection (mean age, 52 years; 138 [58%] women), 221 (92%) completed the trial. At 6-month follow-up, mean VISA-A score values in the plasma-rich plasma group vs the sham injection group were 54.4 vs 53.4 (adjusted mean difference, -2.7 [95% CI, -8.8 to 3.3]). The most common adverse events compared between patients in the platelet-rich plasma group vs the sham group were injection site discomfort (97 vs 73 patients), swelling (56 vs 52 patients) and bruising (48 vs 49 patients). CONCLUSIONS AND RELEVANCE: Among patients with chronic midportion Achilles tendinopathy, treatment with a single injection of intratendinous platelet-rich plasma, compared with insertion of a subcutaneous dry needle, did not reduce Achilles tendon dysfunction at 6 months. These findings do not support the use of this treatment for chronic midportion Achilles tendinopathy. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN13254422.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kearney RS, Ji C, Warwick J, et al. Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial. JAMA. 2021. PMID: 34255009. doi:10.1001/jama.2021.6986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。